Uno Minda Ups Minda Onkyo Stake to 99%; Lupin Launches US Drug

Uno Minda has significantly consolidated its position in Minda Onkyo India (MOIPL), increasing its total stake to an overwhelming 99%. This move comes as the company acquired an additional 19% equity from Onkyo Sound Corporation, Japan.

This strategic acquisition involved 1,51,40,352 equity shares, marking a decisive step towards near-complete ownership. The increased stake positions Uno Minda to exert greater control over MOIPL’s operations and future direction.

Such consolidation often streamlines decision-making and aligns subsidiary activities more closely with the parent company’s broader corporate strategy. It reflects a clear intent to integrate MOIPL further into Uno Minda’s core business.

Lupin Expands US Pharmaceutical Presence

In a separate key development, pharmaceutical major Lupin has successfully launched its Sugammadex Injection in the United States. This launch follows crucial approval from the United States Food and Drug Administration (U.S. FDA) for its abbreviated new drug application.

The Sugammadex Injection is now available in specific formulations: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. This introduction expands Lupin’s portfolio within the critical US market.

Lupin’s product is bioequivalent to Bridion Injection, developed by Merck, Sharp & Dohme LLC (Merck). It serves as an important medical solution for reversing neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.

These distinct corporate actions underscore ongoing strategic realignments and market expansions within the Indian business landscape. Uno Minda strengthens its operational control, while Lupin secures a significant entry into a specialized segment of the competitive U.S. pharmaceutical market.